Why Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Rose 19.0% on Jul 22, 2026
What happened
Arrowhead Pharmaceuticals surged 24.21% to $92.56 on positive Phase 3 topline results for plozasiran announced July 22. The SHASTA-3 and SHASTA-4 studies showed large triglyceride reductions and fewer acute pancreatitis events versus placebo, per Investing.com. Volume reached 2.76M shares—nearly 6x the time-adjusted average—reflecting elevated investor interest.
Regulatory filing timeline for plozasiran and any updates on additional SHASTA study data or label breadth discussions with the FDA.
Frequently asked questions
Why did Arrowhead Pharmaceuticals, Inc. (ARWR) stock rise on Jul 22, 2026?
Arrowhead Pharmaceuticals surged 24.21% to $92.56 on positive Phase 3 topline results for plozasiran announced July 22. The SHASTA-3 and SHASTA-4 studies showed large triglyceride reductions and fewer acute pancreatitis events versus placebo, per Investing.com. Volume reached 2.76M shares—nearly 6x the time-adjusted average—reflecting elevated investor interest.
How much did ARWR stock rise on Jul 22, 2026?
ARWR rose 19.0% during the Jul 22, 2026 trading session.